2018 ASCO

Best Practices: Use of Biomarkers in the Treatment of Patients with Lung Cancer

Roy S. Herbst, MD, PhD; David L. Rimm, MD, PhD

August 2018, Vol 8, No 8 - 2018 ASCO, Interview with the Innovators

At ASCO 2018, Oncology Practice Management (OPM) spoke with Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Director for Translational Research at Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT, and David L. Rimm, MD, PhD, Professor of Pathology, Yale University School of Medicine, about the increasing role of biomarkers in the management of patients with lung cancer. [ Read More ]